SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: EX-1.1
Date Filed: 2026-03-18
Accession Number: 0001493152-26-010642
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226010642/ex1-1.htm

Chunk 4 of 21
Word Count: 1402
Character Count: 9192

Document Content:

to require the Company to register any such securities of the Company under the Securities Act or to include any such securities in a registration statement to be filed by the Company. Validity and Binding Effect of Agreement. This Agreement has been duly and validly authorized by the Company, and, when executed and delivered, will constitute, the valid and binding agreements of the Company, enforceable against the Company in accordance with their respective terms, except: (i) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights generally; (ii) as enforceability of any indemnification or contribution provision may be limited under the federal and state securities laws; and (iii) that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought.

No Conflicts, etc. The execution, delivery and performance by the Company of this Agreement, the Representative’s Warrants
and all ancillary documents, the consummation by the Company of the transactions herein and therein contemplated and the compliance by
the Company with the terms hereof and thereof do not and will not, with or without the giving of notice or the lapse of time or both:
(i) result in a breach of, or conflict with any of the terms and provisions of, or constitute a material default under, or result in
the creation, modification, termination or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant
to the terms of any agreement or instrument to which the Company is a party; (ii) result in any violation of the provisions of the organizational
or governing documents of the Company; or (iii) violate any existing applicable law, rule, regulation, judgment, order or decree of any
Governmental Entity as of the date hereof (including, without limitation, those enforced by the U.S. Food and Drug Administration (the
“FDA”) or by any foreign, federal, state or local regulatory authority performing functions similar to those performed
by the FDA) except in the case of clauses (i) and (iii) for any such breach, conflict, violation, default, lien, charge or encumbrance
that would not reasonably be expected to result in, individually or in the aggregate, a Material Adverse Change.

No Defaults; Violations. No material default exists in the due performance and observance of any term, covenant or condition of
any material license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement or instrument
evidencing an obligation for borrowed money, or any other material agreement or instrument to which the Company or and of its Subsidiaries
is a party or by which the Company or any of its Subsidiaries may be bound or to which any of the properties or assets of the Company
or any of its Subsidiaries is subject. The Company and each of its Subsidiaries is not (i) in violation of any term or provision of its
organizational or governing documents, (ii) in violation of any franchise, license or permit, or (iii) in violation of applicable law,
rule, regulation, judgment or decree of any Governmental Entity (including, without limitations, those administered by the FDA or by
any foreign, federal, state or local regulatory authority performing functions similar to those performed by the FDA) except in the case
of clause (ii) and (iii) for any such violation that would not reasonably be expected to result in, individually or in the aggregate,
a Material Adverse Change.

Corporate Power; Licenses; Consents.

Conduct of Business. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the
Company has all requisite corporate power and authority, and has all necessary material authorizations, approvals, orders, licenses,
registrations, certificates and permits of and from all governmental regulatory officials and bodies (including, without limitation,
the FDA and any foreign, federal, state or local regulatory authority performing functions similar to those performed by the FDA) (collectively,
the “Approvals”), that it needs as of the date hereof to conduct its business as described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, except for any such Approvals the absence of which would not be reasonably expected
to have a Material Adverse Change.

Transactions Contemplated Herein. The Company has all corporate power and authority to enter into this Agreement and to issue
the Representative’s Warrants and to carry out the provisions and conditions hereof and thereof, and all consents, authorizations,
approvals and orders required in connection therewith have been obtained. No consent, authorization or order of, and no filing with,
any court, government agency or other body is required for the valid issuance, sale and delivery of the Public Shares, the Representative’s
Warrants and the Representative Warrant Shares and the consummation of the transactions and agreements contemplated by this Agreement
and the Representative’s Warrants as contemplated by the Registration Statement, the Pricing Disclosure Package and the Prospectus,
except (i) such consents, approvals, authorizations, orders, filings, registrations or qualifications that have already been obtained
or made and (ii) with respect to applicable federal and state securities laws and the rules and regulations of the Financial Industry
Regulatory Authority, Inc. (“FINRA”).

D&O Questionnaires. To the Company’s knowledge, all information contained in the questionnaires (the “Questionnaires”)
completed by each of the Company’s directors and executive officers immediately prior to the Offering (the “Insiders”)
as supplemented by all information concerning the Company’s directors, executive officers and principal stockholders as described
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as well as in the Lock-Up Agreement (as defined in
Section 2.24 below), provided to the Underwriters, is true and correct in all material respects and the Company has not become aware
of any information which would cause the information disclosed in the Questionnaires to become materially inaccurate and incorrect.

Litigation; Governmental Proceedings. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or
governmental proceeding pending or, to the Company’s knowledge, threatened against, or involving the Company or any of its Subsidiaries
or, to the Company’s knowledge, any executive officer or director which has not been disclosed in the Registration Statement, the
Pricing Disclosure Package and the Prospectus or in connection with the Company’s listing application for the listing of the Public
Shares and the Representative Warrant Shares on the Exchange, except as would not reasonably be expected to have, individually or in
the aggregate, a Material Adverse Change.

Good Standing. The Company and each of its Subsidiaries have been duly incorporated and are validly existing as corporations or
other legal entities in good standing (or such equivalent concept in a given jurisdiction, as applicable) as of the date hereof under
the laws of the respective jurisdiction where the entity is organized, and are in good standing in each other jurisdiction in which its
ownership or lease of property or the conduct of business requires such qualification, except where the failure to be so qualified, singularly
or in the aggregate, would not reasonably be expected to result in a Material Adverse Change.

Insurance. On the Closing Date, the Company and its Subsidiaries will carry or will be entitled to the benefits of insurance with,
to the Company’s knowledge, reputable insurers, in such amounts and covering such risks which the Company believes are adequate,
including, but not limited to, directors and officers insurance coverage and all such insurance is in full force and effect. The Company
has no reason to believe that the Company or its Subsidiaries will not be able (i) to renew the existing insurance coverage as and when
such policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its
business as now conducted and at a cost that would not reasonably be expected to result in a Material Adverse Change.

Transactions Affecting Disclosure to FINRA.

Finder’s Fees. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there
are no claims, payments, arrangements, agreements or understandings relating to the payment of a finder’s, consulting or origination
fee by the Company or any Insider with respect to the sale of the Public Shares, the Representative’s Warrants or the Representative
Warrant Shares hereunder or any other arrangements, agreements or understandings of the Company or, to the Company’s knowledge,
any of its stockholders that may affect the Underwriters’ compensation, as determined by FINRA.